Andrew Karter to Cardiovascular Diseases
This is a "connection" page, showing publications Andrew Karter has written about Cardiovascular Diseases.
Connection Strength
1.857
-
Severe Hypoglycemia and Risk of Atherosclerotic Cardiovascular Disease in Patients With Diabetes. Diabetes Care. 2021 03; 44(3):e40-e41.
Score: 0.495
-
Risk of Cardiovascular Events in Patients With Type 2 Diabetes and Metabolic Dyslipidemia Without Prevalent Atherosclerotic Cardiovascular Disease. Am J Med. 2020 02; 133(2):200-206.
Score: 0.446
-
Smoking and Risk of Premature Atherosclerotic Cardiovascular Disease. Am J Prev Med. 2022 03; 62(3):466-468.
Score: 0.131
-
Medication Adherence Does Not Explain Black-White Differences in Cardiometabolic Risk Factor Control among Insured Patients with Diabetes. J Gen Intern Med. 2016 Feb; 31(2):188-195.
Score: 0.088
-
Who Must We Target Now to Minimize Future Cardiovascular Events and Total Mortality?: Lessons From the Surveillance, Prevention and Management of Diabetes Mellitus (SUPREME-DM) Cohort Study. Circ Cardiovasc Qual Outcomes. 2015 Sep; 8(5):508-16.
Score: 0.085
-
Medicare Star excludes diabetes patients with poor CVD risk factor control. Am J Manag Care. 2014 Dec 01; 20(12):e573-81.
Score: 0.081
-
Predictors of mortality over 8 years in type 2 diabetic patients: Translating Research Into Action for Diabetes (TRIAD). Diabetes Care. 2012 Jun; 35(6):1301-9.
Score: 0.067
-
Place matters: neighborhood deprivation and cardiometabolic risk factors in the Diabetes Study of Northern California (DISTANCE). Soc Sci Med. 2012 Apr; 74(7):1082-90.
Score: 0.066
-
Temporal trends in recording of diabetes on death certificates: results from Translating Research Into Action for Diabetes (TRIAD). Diabetes Care. 2011 Jul; 34(7):1529-33.
Score: 0.064
-
Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011 Jun; 34(6):1329-36.
Score: 0.063
-
Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD). Pharmacoepidemiol Drug Saf. 2010 Jul; 19(7):715-21.
Score: 0.059
-
A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care. 2010 Sep; 33(9):2104-9.
Score: 0.059
-
Understanding the gap between good processes of diabetes care and poor intermediate outcomes: Translating Research into Action for Diabetes (TRIAD). Med Care. 2007 Dec; 45(12):1144-53.
Score: 0.050
-
Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care. 2004 Sep; 27(9):2234-40.
Score: 0.040
-
Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol. 2013 Nov; 1(3):183-90.
Score: 0.018
-
Treatment intensification and risk factor control: toward more clinically relevant quality measures. Med Care. 2009 Apr; 47(4):395-402.
Score: 0.014
-
Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008 May; 23(5):588-94.
Score: 0.013
-
Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes. 2004 Jun; 53(6):1549-55.
Score: 0.010
-
Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes. 2002 Aug; 51(8):2642-7.
Score: 0.009